Invesco’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.52B | Buy |
7,892,611
+39,878
| +0.5% | +$18.6M | 0.34% | 39 |
|
|
2025
Q4 | $3.56B | Buy |
7,852,733
+5,755,936
| +275% | +$2.48B | 0.34% | 41 |
|
|
2025
Q3 | $821M | Buy |
2,096,797
+112,751
| +6% | +$47.1M | 0.13% | 166 |
|
|
2025
Q2 | $883M | Buy |
1,984,046
+138,406
| +7% | +$63.8M | 0.15% | 137 |
|
|
2025
Q1 | $895M | Sell |
1,845,640
-52,817
| -3% | -$24.6M | 0.17% | 120 |
|
|
2024
Q4 | $765M | Sell |
1,898,457
-45,147
| -2% | -$20.9M | 0.14% | 149 |
|
|
2024
Q3 | $904M | Buy |
1,943,604
+140,862
| +8% | +$67.7M | 0.17% | 115 |
|
|
2024
Q2 | $845M | Sell |
1,802,742
-288,401
| -14% | -$125M | 0.18% | 105 |
|
|
2024
Q1 | $874M | Sell |
2,091,143
-150,964
| -7% | -$63.8M | 0.19% | 102 |
|
|
2023
Q4 | $912M | Buy |
2,242,107
+225,327
| +11% | +$83.2M | 0.22% | 84 |
|
|
2023
Q3 | $701M | Buy |
2,016,780
+67,451
| +3% | +$23.6M | 0.19% | 108 |
|
|
2023
Q2 | $686M | Buy |
1,949,329
+87,961
| +5% | +$29.6M | 0.18% | 112 |
|
|
2023
Q1 | $586M | Buy |
1,861,368
+236,469
| +15% | +$70.9M | 0.16% | 138 |
|
|
2022
Q4 | $469M | Buy |
1,624,899
+305,217
| +23% | +$93M | 0.14% | 180 |
|
|
2022
Q3 | $382M | Buy |
1,319,682
+196,888
| +18% | +$56.6M | 0.12% | 203 |
|
|
2022
Q2 | $316M | Sell |
1,122,794
-87,563
| -7% | -$23.4M | 0.1% | 274 |
|
|
2022
Q1 | $316M | Buy |
1,210,357
+88,199
| +8% | +$20.9M | 0.08% | 339 |
|
|
2021
Q4 | $246M | Sell |
1,122,158
-92,335
| -8% | -$18M | 0.06% | 438 |
|
|
2021
Q3 | $220M | Buy |
1,214,493
+48,410
| +4% | +$9.45M | 0.06% | 447 |
|
|
2021
Q2 | $235M | Buy |
1,166,083
+197,494
| +20% | +$41.3M | 0.06% | 450 |
|
|
2021
Q1 | $208M | Sell |
968,589
-129,332
| -12% | -$28.4M | 0.06% | 454 |
|
|
2020
Q4 | $259M | Sell |
1,097,921
-33,046
| -3% | -$7.58M | 0.08% | 336 |
|
|
2020
Q3 | $308M | Buy |
1,130,967
+11,258
| +1% | +$3.11M | 0.1% | 228 |
|
|
2020
Q2 | $325M | Sell |
1,119,709
-182,032
| -14% | -$49.4M | 0.12% | 202 |
|
|
2020
Q1 | $310M | Buy |
1,301,741
+207,470
| +19% | +$47.6M | 0.13% | 182 |
|
|
2019
Q4 | $240M | Sell |
1,094,271
-2,565,660
| -70% | -$519M | 0.07% | 337 |
|
|
2019
Q3 | $620M | Sell |
3,659,931
-403,977
| -10% | -$71.5M | 0.16% | 135 |
|
|
2019
Q2 | $745M | Buy |
4,063,908
+335,938
| +9% | +$58.7M | 0.19% | 102 |
|
|
2019
Q1 | $686M | Buy |
3,727,970
+21,753
| +0.6% | +$4.02M | 0.23% | 88 |
|
|
2018
Q4 | $614M | Sell |
3,706,217
-11,713
| -0.3% | -$2.03M | 0.24% | 87 |
|
|
2018
Q3 | $717M | Sell |
3,717,930
-77,449
| -2% | -$13.8M | 0.23% | 94 |
|
|
2018
Q2 | $645M | Buy |
3,795,379
+515,949
| +16% | +$80M | 0.21% | 100 |
|
|
2018
Q1 | $534M | Buy |
3,279,430
+169,936
| +5% | +$27.8M | 0.2% | 118 |
|
|
2017
Q4 | $466M | Buy |
3,109,494
+14,479
| +0.5% | +$2.14M | 0.17% | 136 |
|
|
2017
Q3 | $471M | Sell |
3,095,015
-166,710
| -5% | -$25.1M | 0.17% | 138 |
|
|
2017
Q2 | $420M | Buy |
3,261,725
+328,399
| +11% | +$39.5M | 0.13% | 168 |
|
|
2017
Q1 | $321M | Buy |
2,933,326
+29,887
| +1% | +$2.63M | 0.11% | 217 |
|
|
2016
Q4 | $214M | Sell |
2,903,439
-163,512
| -5% | -$13.3M | 0.07% | 289 |
|
|
2016
Q3 | $267M | Sell |
3,066,951
-105
| -0% | -$9.92K | 0.09% | 245 |
|
|
2016
Q2 | $264M | Sell |
3,067,056
-258,054
| -8% | -$22.3M | 0.1% | 232 |
|
|
2016
Q1 | $264M | Sell |
3,325,110
-926,098
| -22% | -$83.8M | 0.11% | 216 |
|
|
2015
Q4 | $535M | Buy |
4,251,208
+164,266
| +4% | +$19.8M | 0.21% | 98 |
|
|
2015
Q3 | $426M | Buy |
4,086,942
+334,402
| +9% | +$43M | 0.18% | 118 |
|
|
2015
Q2 | $463M | Buy |
3,752,540
+233,736
| +7% | +$29.5M | 0.18% | 124 |
|
|
2015
Q1 | $415M | Buy |
3,518,804
+432,823
| +14% | +$51.9M | 0.16% | 142 |
|
|
2014
Q4 | $367M | Buy |
3,085,981
+234,511
| +8% | +$26.4M | 0.14% | 165 |
|
|
2014
Q3 | $320M | Sell |
2,851,470
-153,621
| -5% | -$14.6M | 0.13% | 189 |
|
|
2014
Q2 | $285M | Sell |
3,005,091
-157,853
| -5% | -$11.1M | 0.11% | 217 |
|
|
2014
Q1 | $224M | Sell |
3,162,944
-94,408
| -3% | -$7.48M | 0.09% | 270 |
|
|
2013
Q4 | $242M | Buy |
3,257,352
+156,515
| +5% | +$10.9M | 0.1% | 254 |
|
|
2013
Q3 | $235M | Buy |
3,100,837
+231,466
| +8% | +$18.4M | 0.1% | 232 |
|
|
2013
Q2 | $230M | Buy |
+2,869,371
| New | +$211M | 0.11% | 215 |
|
Other funds holding VRTX
VCM
VPM
Invesco's VRTX Position: Q1 2026 in Review
Invesco increased its Vertex Pharmaceuticals (VRTX) stake by 0.51% in Q1 2026, buying an estimated $18.6M and bringing the position to 7,892,611 shares worth $3.52B. The position accounts for 0.34% of the portfolio, ranked #39.
Invesco first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.56B in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Invesco held 7,892,611 shares of Vertex Pharmaceuticals worth $3.52B as of Q1 2026.
- Invesco bought 39,878 Vertex Pharmaceuticals shares in Q1 2026, an estimated $18.6M.
- Vertex Pharmaceuticals made up 0.34% of Invesco's portfolio in Q1 2026, its #39 holding.
- Invesco first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Invesco's Vertex Pharmaceuticals position peaked at $3.56B in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.